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Fragile X syndrome (FX), the most common heritable cause of mental retardation and autism, is a developmental disorder
characterized by physical, cognitive, and behavioral deficits. FX results from a trinucleotide expansion mutation in the fmr1
gene that reduces levels of fragile X mental retardation protein (FMRP). Although research efforts have focused on FMRP’s
impact on mGluR signaling, how the loss of FMRP leads to the individual symptoms of FX is not known. Previous studies on
human FX blood cells revealed alterations in the cyclic adenosine 39,5 9-monophosphate (cAMP) cascade. We tested the
hypothesis that cAMP signaling is altered in the FX nervous system using three different model systems. Induced levels of
cAMP in platelets and in brains of fmr1 knockout mice are substantially reduced. Cyclic AMP induction is also significantly
reduced in human FX neural cells. Furthermore, cAMP production is decreased in the heads of FX Drosophila and this defect
can be rescued by reintroduction of the dfmr gene. Our results indicate that a robust defect in cAMP production in FX is
conserved across species and suggest that cAMP metabolism may serve as a useful biomarker in the human disease
population. Reduced cAMP induction has implications for the underlying causes of FX and autism spectrum disorders.
Pharmacological agents known to modulate the cAMP cascade may be therapeutic in FX patients and can be tested in these
models, thus supplementing current efforts centered on mGluR signaling.
Citation: Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JCP, et al (2007) The Cyclic AMP Cascade Is Altered in the Fragile X Nervous System. PLoS
ONE 2(9): e931. doi:10.1371/journal.pone.0000931
INTRODUCTION
Fragile X syndrome (FX) is characterized by physical, cognitive,
and behavioral deficits [1]. A CGG trinucleotide expansion in the
fmr1 gene suppresses production of the FX mental retardation
protein (FMRP), an RNA binding protein that regulates trans-
lation through interaction with dendritic ribosomes and has a role
in mRNA shuttling [2–5]. Both mouse and Drosophila models of
FX have been characterized [6,7]. Rodent models are surprisingly
mild in their phenotypes compared to the severity of the human
disease. Drosophila models show stronger phenotypes with defects
in brain development, axon pathfinding, and effects on courtship-
based learning and memory formation and circadian rhythms. A
major advance occurred when Huber and Bear reported deficits in
synaptic plasticity in FX mice. Their ‘‘mGluR theory of FX’’
proposes that there is excessive signaling through the mGluR5
subtype of glutamatergic receptors [8]. Experiments in hippocam-
pus show that a form of synaptic plasticity, long-term depression
(LTD), can be induced with either type I mGluR (mGluR1 and
mGluR5) agonists or with low frequency electrical stimulation [9].
LTD persistence requires de novo protein synthesis and, re-
markably, involves FMRP. FX mice show excessive LTD,
suggesting that FMRP is normally involved in a pathway
terminating this type of LTD. Contemporaneously, FX mice were
shown to be sensitive to audiogenic seizures, a striking phenotype
similar to some FX patients who also suffer seizures [10]. Key
pharmacological experiments in both models show that mGluR5
antagonists can reverse most, but not all, of the endophenotypes
[8,11,12]. It is therefore possible that there are other defects within
the FX brain that are not reversible when mGluR signaling is
inhibited.
In the early 1990s, Berry-Kravis and colleagues postulated that
another intracellular signaling pathway, cyclic AMP (cAMP),
contributes to FX neuropathophysiology [13]. Cyclic AMP is
produced by adenylate cyclase (AC), degraded by phosphodies-
terase (PDE), and can bind PKA, GEFs, and CNG channels. AC
can be stimulated by G proteins or forskolin and modulated by
Ca
2+, G proteins, PKA, PKC, and CaMK [14]. The cAMP system
is critical in many aspects of neural development [15] and may be
important in autism susceptibility [16,17]. Cyclic AMP production
is decreased in non-neural cells from FX patients and this
alteration is FMRP dependent [18,19]. This ‘‘cAMP theory of
FX’’ posits that alterations in the cAMP pathway may result from
dysregulated expression of proteins involved in the cAMP cascade
either (1) in parallel with the mGluR theory using a mechanism
independent of mGluR or (2) in series with the mGluR theory
through a mechanism downstream of mGluR overactivity.
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of phenotypes achievable using mGluR antagonists suggest that
excessive mGluR signaling is difficult to correct within the mGluR
pathway or that parallel pathways are involved. Therefore, we
investigated the cAMP theory in the FX central nervous system.
We tested whether the cAMP defect is conserved across species,
thereby indicating a common mechanism for the cAMP defect. If
FMRP loss limits cAMP production in the FX brain in vivo,
pharmacologic agents known to act through the cAMP cascade
may be therapeutic to FX patients.
RESULTS
To test the hypothesis that there is a highly conserved relationship
between FMRP and cAMP activity, we examined cAMP
production in mouse, fly and human systems containing a non-
functional fmr1 gene. Forskolin is a general activator of adenylate
cyclases. Berry-Kravis and Sklena reported that normal human
platelets show a greater forskolin-mediated increase in cAMP than
platelets from individuals with FX [20]. We investigated this effect
in wild-type and fmr1 knockout mouse platelets using a fluores-
cence-based assay, where raw fluorescence (RF) decreases when
cAMP levels increase. Figure 1a shows that untreated platelets
have similar levels of RF, but forskolin treated wild-type platelets
show a greater decrease than comparably treated fmr1 knockout
platelets. When the fractional decrease in RF (FDRF) is calculated,
fmr1 knockout mouse platelets show less of a decrease (indicating
reduced cAMP induction) compared to wild type platelets [t(6)=
3.46; p=0.014] (Figure 1b).
To extend these results to brain, we measured cAMP levels from
wild-type and fmr1 knockout mouse cortical membranes.
Although the RF was comparable between groups in the absence
[t(4)=1.22; p=0.29] or presence [t(4)=21.92; p=0.13] of
forskolin (Figure 1c), the FDRF is significantly less in fmr1
knockout tissue than wild-type tissue, indicating that the FX
cortical tissue shows reduced cAMP induction [t(4)=3.01; p=
0.04] (Figure 1d). To determine whether the cAMP defect is
a ubiquitous feature of the FX knockout mouse phenotype, cAMP
responses to forskolin from platelets and cortex from wild-type and
fmr1 knockout mice were compared as a contrast within a three
way ANOVA (GroupxStimulusxOrganSystem). The fmr1 knock-
out brain and blood consistently produce less cAMP than wild-
type tissue based on RF measures [GroupxStimulus: F(1,20)=
10.50; p=0.004] and FDRF [F(1,10)=14.92; p=0.003].
Using the Drosophila model, we varied the gene dosage of the
fly FX gene (dfmr1) (0=FX, 1=FXR+, 2=FXR++), and
measured cAMP production from head membrane preparations
in the presence or absence of forskolin. RF-based cAMP measures
are comparable among wild-type, FX, FXR+, and FXR++ flies in
the absence of forskolin [F(3,21)=1.96; p=0.15]. However, in the
presence of forskolin [F(3,21)=6.23; p=0.003], FX flies have
a larger RF compared to all other groups taken collectively,
Figure 1. cAMP production is decreased in FX mice. Platelets (Control n=3, FX n=5) and cortical membranes (n=3 for each group) from wildtype
and fmr1 knockout mice were stimulated with forskolin and levels of cAMP were measured (each n averaged in triplicate). Raw fluorescence (RF) is an
inverse index of cAMP levels. The change in cAMP production was assessed using the fractional decrease in RF (FDRF)=(No Forskolin2Forskolin)/(No
Forskolin). (a) Mouse platelet RF is comparable in the absence of forskolin [t(6)=0.99; p=0.36] but significantly different between groups
(GroupxStimulus:[F(1,12)=7.56;p=0.018]) in the presence of forskolin [t(6)=22.62; p=0.040]. (b) Mouse platelet FDRF shows reduced cAMP
induction in FX platelets [t(6)= 3.46; p=0.014]. (c) Mouse cortex RF is comparable between groups in the absence [t(4)=1.22;p=0.29] or presence
[t(4)=21.92;p=0.13] of forskolin. (d) Mouse cortex FDRF shows reduced FX cAMP induction [t(4)=3.01; p=0.04]. Error bars are SEM.
doi:10.1371/journal.pone.0000931.g001
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p=0.005], FXR+[t(21)= 23.74; p=0.001], and FXR++ [t(21)=
24.10; p=0.001]). In the presence of forskolin, the wild-type flies
are indistinguishable from the rescue flies [t(21)=1.61; p=0.123]
with a single [FXR+ FDRF:t(21)=1.09; p=0.29] or multiple
transgenes [FXR++ FDRF:t(21)=1.58; p=0.13] (Figure 2a).
cAMP production, as assessed using FDRF, is comparable among
wild-type and the group of rescued flies [FDRF:t(21)=20.155;
p=0.88] with one [FXR+ FDRF:t(21)=0.485; p=0.632] or two
transgenes [FXR++ FDRF:t(21)=20.74; p=0.46]. However,
FDRF and thus cAMP induction, is diminished in FX relative to
wild-type membranes [FDRF:t(21)=3.85; p=0.001], or relative
to the group of rescued FX flies [FDRF:t(21)=4.03; p=0.001]
with a single [FXR+ FDRF:t(21)=3.23; p=0.004] or multiple
transgenes [FXR++ FDRF:t(21)=4.13; p=0.000] (Figure 2b).
Therefore, FX mutant flies show less of an induction in cAMP in
response to forskolin, and either one or two rescue transgenes
alleviate this effect.
To extend these experiments to human cells, we examined
forskolin’s effects on cultures of human FX and unaffected control
neural cells. Both control and FX cultures contain neurons and
astrocytes (Figure 3a), but the FX cells express markedly less
FMRP than control cells (Figure 3b). Levels of cAMP in FX
human neural cells are comparable to control cells in the absence
of forskolin [RF:t(6)=0.82; p=0.44] . However, when the cultures
are treated with forskolin, FX cultures produce lower levels of
cAMP than controls [RF:t(6)=23.40; p=0.015] (Figure 3c). The
fractional change in cAMP production is differentially reduced in
FX compared to both controls [FDRF:t(6)=3.43; p=0.01]
(Figure 3d) indicating that the FX neural cells show reduced
cAMP induction.
DISCUSSION
Although FX etiology is well defined, individual differences in
syndrome expression and symptoms complicate current options
for treatment. To define therapeutic pathways to target, it is
important to identify cellular processes affected in the FX brain.
Based on previous work, we compared the inducibility of cAMP
across neural models and found that cAMP induction is decreased
in the FX fly, mouse and human nervous system.
The alterations we detect in FX nervous tissue have broad
implications, since cAMP signaling has widespread cellular
impact, potentially affecting channel function, signal transduction
(GEFs and EPAC) and gene expression (CREB) [15]. The
conservation of the cAMP defect in fly, mouse and human species
suggests that cAMP metabolism may serve as a useful biomarker in
the human disease population, and may account for some of the
differences in clinical endophenotypes. An important corollary is
that increasing cAMP levels could improve neuronal function and
behavior in FX patients. Precedent exists for pharmacological
rescue of FX behavior, since lithium or mGluR5 antagonists
improve behavior in Drosophila memory formation [12].
However, it is not known if these treatments affect cAMP
inducibility, or otherwise target the cAMP pathway. The prospect
of using PDE4 inhibitors, such as rolipram or HT0712, is
particularly appealing, since memory enhancement through
facilitation of cAMP signaling may be possible without changing
basal cAMP levels [21,22]. There are numerous candidate
mechanisms that might contribute to cAMP rescue of FX neural
defects, including different effects on cAMP signaling, or cross talk
with the MAPK, PKC, and/or IP3/Ca
2+ pathways.
How does a decrease in FMRP lead to alterations in cAMP?
FMRP is an mRNA binding protein that shuttles subsets of
mRNA between the nucleus and subcellular compartments such as
neuronal dendrites. Gene expression analyses in FX models
suggest that the mRNAs for adenylate cyclase types 3, 5 and 6
might be decreased in FX tissue [23–25]. The decrease in steady-
state concentrations of other candidate mRNAs could also
contribute to the alterations in cAMP metabolism that we observe.
In support of the cAMP theory, our results identify cAMP
alterations in the FX nervous system that may account for some of
the neuropathophysiology of FX. Several lines of evidence support
the view that mGluR and cAMP mediated pathways functionally
interact in platelets [26], lymphocytes [27], neurons [28–32] and
astrocytes [33]. However, further studies are required to clarify the
series or parallel relationship between the cAMP and mGluR
defects in FX. For example, rescue of cAMP deficits in FX with
mGluR inhibitors would suggest that the pathways operate in
series, with the cAMP defect presumably downstream of excessive
mGluR activity. Lack of, or incomplete rescue, would support
a parallel mechanism where proteins that are directly involved in,
or that interact with, the cAMP cascade are dysregulated by
Figure 2. cAMP production is decreased in FX fly. Head membranes
from wildtype, FX, FXR+, FXR++ flies were stimulated with forskolin and
levels of cAMP were measured. Raw fluorescence (RF) is an inverse
index of cAMP levels. The change in cAMP production was assessed
using the fractional decrease in RF (FDRF)=(No Forskolin2Forskolin)/
(No Forskolin). (a) RF-based cAMP measures in the fly head (Control
n=10, FX n=3, FXR+ n=6; FXR++ n=6 sets of 20 heads) are
comparable between groups in the absence of forskolin
[F(3,21)=1.96; p=0.15], but not its presence [F(3,21)=6.23;p=0.003],
since RF intensity in FX flies is larger than the others
[t(21)=24.10;p=0.000]. (b) Fly head FDRF shows reduced FX cAMP
induction relative to control membranes [FDRF:t(21)=3.85;p=0.001]
and to the FX flies rescued with a single or multiple transgenes
[FXR+FDRF:t(21)=3.23;p=0.004; FXR++FDRF:t(21)=4.13;p=0.000]. Er-
ror bars are SEM.
doi:10.1371/journal.pone.0000931.g002
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specific mechanism of FMRP interaction with the cAMP cascade
and the conserved upstream, downstream, and behavioral
consequences of reduced cAMP induction can be studied within
and across FX mouse, fly, and human models. Most importantly,
this work lays the groundwork for future therapeutic options on
FX, thus complementing current approaches focused on the
mGluR pathway.
MATERIALS AND METHODS
Mouse Platelet Membrane Preparation
Whole mouse blood (,0.75 ml/mouse) was collected from the first
systolic ejection upon decapitation and collected in EDTA solution
(1mg EDTA/ml whole blood). Within 2 hours of collection, blood
samples were centrifuged at 7006g for 10 minutes at room
temperature [34]. The upper platelet-rich plasma layer (UPRP)
was transferred to a fresh centrifuge tube and centrifuged at
7006g for 10 minutes at room temperature. The UPRP plasma
was centrifuged at 28006g for 15 minutes at room temperature.
The platelet pellet was stored at –70uC until assayed. Pellets were
thawed on ice and centrifuged at 170006g in a microfuge for
10 minutes. Protein levels were determined with the Lowry
protein assay (Bio-Rad Laboratories, Hercules, CA). 100ug protein
was incubated in Krebs-Ringer Bicarbonate buffer (KRB) with 3-
isobutyl-1methylxanthine (IBMX; a non-selective PDE inhibitor)
at 37uC for 20 minutes in the presence of ATP plus forskolin
(5 mM; solubilized in DMSO; Sigma, St. Louis, MO) or DMSO
alone and then assayed for cAMP.
Mouse Brain Cortical Membrane Preparation
Cerebral cortices were harvested from three-month old wild type
and age-matched FX (fmr1 knockout) male C57/Bl6 mice. Tissue
was homogenized in 25 mM HEPES, 2 mM EGTA, pH 7.4, and
centrifuged at 7506g for 10 minutes at 4uC. The supernatant was
centrifuged at 45,0006g for 60 minutes at 4uC [35]. Pellets were
resuspended in HEPES buffer and stored at –80uC until assayed.
Cortical membranes were thawed and centrifuged at 170006gi n
a microfuge for 10 minutes at 4uC. The pellet was resuspended in
Figure 3. cAMP production is decreased in human FX neural cells. Unaffected and FX human neural cells were stimulated with forskolin and levels
of cAMP were measured. Raw fluorescence (RF) is an inverse index of cAMP levels. The change in cAMP production was assessed using the fractional
decrease in RF (FDRF)=(No Forskolin2Forskolin)/(No Forskolin). (a) Neurons (MAP2, green) are present among cells (Hoechst stain, nuclei in blue) in
9 week FX cultures. (b) Extracts of human neural cells were immunoblotted with antibodies to FMRP and actin. FX cells (FX) have reduced levels of
FMRP compared to 3 controls (control 1, 2, 3). Similar levels of actin are detected in each sample. (c) Human neural cell RF (2 Controls, each with n=3;
FX, n=3) is comparable between groups in forskolin’s absence [t(6)=0.82; p=0.44] but FX cAMP production is lower than controls in the presence of
forskolin [RF: t(6)=23.40; p=0.015]. (d) Human neural cell FDRF was reduced in FX [t(6)=3.43; p=0.01]. Error bars are SEM for FX and pooled SEM for
controls. (Pooled SEM)
2=SEM1
2+SEM2
222*SEM1*SEM2.
doi:10.1371/journal.pone.0000931.g003
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KRB-IBMX at 37uC for 20 minutes in the presence of ATP plus
forskolin or DMSO and then assayed for cAMP.
Drosophila Head Membrane Preparation
Wild-type, FX, FX plus a dfmr rescue transgene (FXR+), and
FX plus a double dfmr transgene (FXR++) male Drosophila
Melanogaster were frozen, heads isolated, and stored at 270uC
[36]. Fifty heads were homogenized with a motorized pellet pestle
(Kontes; Vineland, NJ) in 100 uL ice-cold homogenization buffer
(15 mM HEPES pH 7.5, 10mM KCl, 5 mM MgCl2, 0.1 mM
EDTA, 0.1 mM EGTA, 5% sucrose, Roche Complete Protease
Inhibitor cocktail tablet). The suspension was allowed to settle
5 min on ice to remove the chitin exoskeleton. To remove eye
pigment, 5mg acid rinsed charcoal was added [37] and the
suspension was centrifuged three times at 2006g for 2 minutes to
remove the charcoal. The supernatant was centrifuged at
14,0006g for 15 minutes and resuspended in 50 uL of 1X
KRB-IBMX. 2 ug Drosophila head membranes was incubated in
KRB-IBMX at 37uC for 20 minutes in the presence of ATP plus
forskolin or DMSO and then assayed for cAMP.
Human Neural Cells
Human FX and unaffected neural cells were differentiated from
FX and unaffected human neural progenitor cells (hNPCs).
Human neural progenitor cells were derived from post-mortem
cerebral cortices of 3 control fetuses (gestational ages 81–98 days)
and a full mutation male Fragile X fetus (gestational age
approximately 98 days) [38]. Human fetal tissue was obtained
according to the guidelines recommended by National Institutes of
Health for the collection of fetal tissue and set out by the
University of Wisconsin-Madison. Institutional Review Board
approval was obtained for all of these studies. FX and control
hNPCs were plated onto laminin/poly-L-lysine flasks in DMEM/
Ham’s F12 media (Invitrogen, Carlsbad CA ) with penicillin,
streptomycin, amphotericin B (PSA, 1%; Invitrogen, Carlsbad
CA) and supplemented with B27 (2%; Invitrogen, Carlsbad CA)
and NT4 (20 ng/ml; Peprotech) for 7 days [39]. Cells were then
dissociated and grown at a density of 5000 cells/ul for 9–12 weeks
in Neurobasal media (Invitrogen, Carlsbad CA ) with penicillin,
streptomycin, amphotericin B (PSA, 1%; Invitrogen, Carlsbad
CA) and glutamine (Sigma, St. Louis, MO) and supplemented
with fetal calf serum (10%; Invitrogen, Carlsbad CA), B27 (2%;
Invitrogen, Carlsbad CA) and NT4 (20ng/ml; Peprotech). For
cAMP assays, cells were enzymatically dissociated and suspended
to a final concentration of 5610
5 cells/ml in KRB-IBMX buffer.
After 15 minutes, cells were stimulated with 50 uM forskolin or
DMSO alone for 30 minutes at room temperature and assayed for
cAMP levels.
Immunocytochemistry Cultures were fixed in 4%
paraformaldehyde and washed in PBS. Fixed cells were blocked
and permeabilized in 5% goat serum with 0.2% Triton X-100 and
subsequently incubated with an antibody to MAP2 (1:1000;
Sigma, St. Louis, MO) followed by incubation with a fluorescent
secondary antibody. Hoechst 33258 (Sigma, St. Louis, MO) was
used as a nuclear stain.
Western blots FX and control neural cells were harvested in
lysis buffer (20 mM Tris, pH 8, 137 mM NaCl, 1% NP-40, 10%
glycerol, protease inhibitors) and cleared by centrifugation. Protein
extracts (25 ug) and molecular weight standards were size
fractionated with SDS-PAGE and immunoblotted with
antibodies to FMRP (Chemicon/Millipore, Billerica, MA) and
actin (Sigma, St. Louis, MO). Proteins were visualized by
incubation with horseradish peroxidase-coupled secondary
antibodies and enhanced chemiluminescence (Amersham
Biosciences), followed by exposure onto x-ray film.
Flourescent cAMP Assay
The Bridge-It cAMP designer fluorescence assay system (Med-
iomics, LLC, St. Louis, MO) was used to measure cyclic AMP
levels in all samples [40]. cAMP is quantified as a reduction in
fluorescence when CAP (cAMP Receptor Protein), a bacterial
transcription factor whose DNA binding affinity is high in the
presence of cAMP and low in cAMP’s absence, binds to DNA
fluorescently tagged at the CAP binding site. Binding quenches
fluorescence. This fluorescence assay has a 5 nM cAMP detection
level and was carried out according to manufacturer’s specifica-
tions. Fluorescence intensity was evaluated by using a Safire II
plate reader (Tecan, Inc., St. Louis, MO). Raw fluorescence (RF)
was used as an index of static cAMP levels at rest and after
stimulation. The change in cAMP production was assessed using
the fractional decrease in RF (FDRF)=(No Forskolin2Forskolin)/
(No Forskolin), a statistic that measures the percentage of
fluorescence quenching and is both reproducible for a given
cAMP level and independent of the instrument used to measure
fluorescence.
Statistical analyses were conducted in SPSS 14.0 (SPSS, Inc,
Chicago, IL) and evaluated for two-tailed significance. All
fluorescence trials were replicated in triplicate unless otherwise
noted. Human cell studies were blinded with respect to FX status
and unblinded for analysis.
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